We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Pink Sheet is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Bluebird bio raises $60mm through oversubscribed Series D venture round
16 Aug 2012
Executive Summary
Gene therapy firm bluebird bio LLC has raised $60mm through an oversubscribed Series D venture round. New backers Deerfield Partners, RA Capital, Ramius Capital Group, and two undisclosed blue chip public investment funds were joined by current shareholders, which collectively invested $15mm: Arch Venture Partners, Third Rock Ventures, TVM Capital, and Forbion Capital Partners, plus eight other unnamed investors. Shire PLC also took part as a strategic investor. The company will use the money to begin a Phase II/III trial of Lenti-D for childhood cerebral adrenoleukodystrophy in the US and Europe next year, and a separate Phase I/II trial of Lentiglobin in the US for beta-thalassemia. Bluebird bio will also continue developing its Lentiglobin sickle cell disease program and expand its manufacturing, clinical, and commercial infrastructure. The financing--the third-largest venture round of the year behind Warp Drive Bio ($125mm) and Agendia ($65mm)--closed just days after the first gene therapy (uniQure BV’s Glybera for lipoprotein lipase deficiency) cleared European regulatory hurdles and received a positive opinion from the EMA recommending approval.
Deal Industry
Pharmaceuticals
Pharmaceuticals
Drug Delivery
Macromolecule
Biotechnology
Gene Therapy, Cell Therapy
Large Molecule
Deal Status
Final
Deal Type
Financing
Venture Financing
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?